Article Text

AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting
  1. J. Kelsall1,
  2. A. Jovaisas2,
  3. P. Rahman3,
  4. D. Sholter4,
  5. M. Starr5,
  6. W.G. Bensen6,
  7. M. Sheriff7,
  8. W. Olszynski8,
  9. M. Zummer9,
  10. R. Faraawi10,
  11. A. Chow11,
  12. S. Kapur12,
  13. E. Rampakakis13,
  14. J. Sampalis13,
  15. F. Nantel14,
  16. S. Otawa14,
  17. M. Shawi14,
  18. A.J. Lehman14
  1. 1Mary Pack Arthritis Centre, Vancouver
  2. 2University of Ottawa, Ottawa
  3. 3Memorial University of Newfoundland, St. John's
  4. 4University of Alberta, Edmonton
  5. 5Montreal General Hospital, Montreal
  6. 6St Joseph's Hospital & McMaster University, Hamilton
  7. 7Nanaimo Regional General Hospital, Nanaimo
  8. 8University of Saskatchewan, Saskatoon
  9. 9Université de Montréal and Hôpital Maisonneuve-Rosemont, Montreal
  10. 10McMaster University, Hamilton
  11. 11Credit Valley Rheumatology, Mississauga
  12. 12Ottawa Hospital, Ottawa
  13. 13McGill University & JSS Medical Research, Montreal
  14. 14Janssen Inc Canada, Toronto, Canada


Background The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials.

Objectives The objective of this analysis was to assess in Canadian routine clinical practice the durability of treatment with infliximab (IFX) in PsA and RA and the determinants associated with sustainability of IFX.

Methods BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab or golimumab as first biologics or after having been treated with a biologic for less than six months. Patients with PsA or RA treated with IFX who were enrolled between 2002 (2005 for PsA patients) and 2012 were included in this analysis. Dose optimization was defined as an increase in the frequency and/or dosing of IFX. Kaplan Meier (KM) estimates and Cox proportional models were used in the analysis.

Results A total of 92 PsA and 830 RA patients were included in the analysis. Mean (SD) age of the PsA and RA patient cohorts was 48.7 (9.9) and 55.8 (13.4) years, respectively, and mean (SD) duration since diagnosis was 6.8 (9.1) and 10.2 (10.1) years, respectively. Twenty seven (29.3%) PsA patients and 407 (49.0%) RA patients had discontinued treatment. Overall KM-based mean (SE) duration of treatment was 41.4 (3.6) months and 61.3 (2.2) months for PsA and RA patients, respectively. Longer treatment duration was associated with significantly greater improvements in pain (parameter estimate PsA: -0.21, P=0.020; RA: -0.27, P<0.001), patient global (PsA: -0.35, P<0.001; RA: -0.28, P<0.001) and HAQ-DI (PsA: -0.01, P<0.001; RA: -0.01, P<0.001). Significant associations with duration of treatment in PsA patients were observed for disease duration (HR=1.04), previous biologic (HR=2.10), baseline TJC28 (HR=1.10), baseline PASI (HR=0.86) and concomitant use of traditional DMARD(s) (HR=0.16) or NSAID(s) (HR=0.38). For RA patients, IFX dose optimization (HR=0.72) and concomitant use of steroids (HR=1.78) were identified as significant predictors of treatment durability.

Conclusions The results of this observational study have shown a high durability of treatment with IFX for patients with PsA or RA in a real-world setting. Concomitant medication use significantly impacts treatment durability. Furthermore, longer disease duration, higher TJC, less severe skin disease at initiation and previous biologic use in PsA, and absence of IFX dose optimization in RA, may be associated with reduced treatment durability.

Disclosure of Interest J. Kelsall: None declared, A. Jovaisas: None declared, P. Rahman: None declared, D. Sholter: None declared, M. Starr: None declared, W. Bensen: None declared, M. Sheriff: None declared, W. Olszynski: None declared, M. Zummer: None declared, R. Faraawi: None declared, A. Chow: None declared, S. Kapur: None declared, E. Rampakakis: None declared, J. Sampalis: None declared, F. Nantel Employee of: Janssen Inc Canada, S. Otawa Employee of: Janssen Inc Canada, M. Shawi Employee of: Janssen Inc Canada, A. Lehman Employee of: Janssen Inc Canada

DOI 10.1136/annrheumdis-2014-eular.4013

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.